胃癌的组织和分子分型与药物个体化治疗  

Histological and molecular classification of gastric cancer and personalized therapy

作　　者：林晓琳[1] 肖秀英[1] 

机构地区：[1]上海交通大学医学院附属仁济医院肿瘤科,上海市200127

出　　处：《世界华人消化杂志》2015年第26期4141-4149,共9页World Chinese Journal of Digestology

基　　金：国家自然科学基金资助项目;No.81101648;上海高校青年教师培养资助计划基金资助项目;No.ZZjdyx13063~~

摘　　要：胃癌是消化系常见的恶性肿瘤之一,大多数患者在就诊时已属于晚期,进展快,预后差.尽管手术、放疗、化疗及靶向等治疗方法不断进步,但总体上进展期胃癌的疗效差,其死亡率居于癌症的第2位.药物治疗作为晚期胃癌主要的治疗方式,在同一病理类型、相同分期的患者,其疗效相差较大.其原因主要是胃癌是一种高度异质性的肿瘤,在肿瘤的生物学行为和患者遗传学方面等有差异.依据现有的病理学分型并不能很好的预测预后、指导治疗,本文旨在通过分析讨论不同组织分型及分子分型与药物的敏感性的关系,以期寻找能够指导临床药物治疗的病理分型和分子分型,为不同患者的个体化治疗方案选择提供理论依据.Gastric cancer is one of the most common malignancies of the digestive system,and the majority of gastric cancer patients have already had advanced disease at diagnosis.Although rapid progress has been made in medical diagnostic equipment,surgical techniques,chemotherapy drugs and targeted therapy,the prognosis of advanced gastric cancer is still poor.Gastric cancer still has the second highest mortality rate among all cancers and is highly heterogeneous in terms of biology and genetics.The existing pathological typing system for gastric cancer cannot well evaluate prognosis and guide treatment.This paper aims to analyze and discuss the relationship between different histological and molecular classification methods and susceptibility to drugs in order to seek a suitable pathological and molecular typing method to guide the personalized therapy of this malignancy.

关 键 词：胃癌 组织分型 分子分型 药物治疗 预后 

分 类 号：R735.2[医药卫生—肿瘤]